The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

Critical Care Medicine

Volumn 30, Issue 5 SUPPL., 2002, Pages

  Zimmerman, Guy A ^a   McIntyre, Thomas M ^a   Prescott, Stephen M ^a   Stafforini, Diana M ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Inflammation; Platelet activating factor; Platelet activating factor acetylhydrolase; Platelet activating factor receptor; Platelet activating factor like lipid; Sepsis; Thrombosis

Indexed keywords

HYDROLASE; THROMBOCYTE ACTIVATING FACTOR;

CONFERENCE PAPER; HUMAN; INFLAMMATION; INJURY; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SHOCK; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 0036250816     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200205001-00020     Document Type: Conference Paper

References (90)

1. Endothelial cell-associated platelet-activating factor: A novel mechanism for signaling intercellular adhesion
2. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils
3. Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: Intracellular PAF-binding sites and activation of a fos/jun/AP-1 transcriptional signaling system
4. Cell-to-cell communication
5. Platelet-activating factor: A phospholipid mediator of inflammation
6. Platelet-activating factor and related lipid mediators
7. Biologically active oxidized phospholipids
8. Platelet-activating factor: A fluid-phase and cell-associated mediator of inflammation
9. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice
10. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor
11. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor
12. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice
13. Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury
14. Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation
15. Platelet-activating factor causes ventilation-perfusion mismatch in humans
16. Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: Interstrain variation and genetic control
17. PAF-induced airways hyperreactivity is modulated by mast cells in mice
18. 2+ response in transformed lymphoblasts
19. Regulation of stably transfected platelet activating factor receptor in RBL-2H3 cells: Role of multiple G proteins and receptor phosphorylation
20. Role of cytoplasmic tail phosphorylation sites of platelet-activating factor receptor in agonist-induced desensitization
21. Cross-desensitization among receptors for platelet activating factor and peptide chemoattractants: Evidence for independent regulatory pathways
22. Agonist-induced sequestration, recycling, and resensitization of platelet-activating factor receptor: Role of cytoplasmic tail phosphorylation in each process
23. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro
24. Downregulation of platelet-activating factor responsiveness during maturation of human dendritic cells
25. Inflammatory roles of P-selectin
26. 2+ mobilization
27. Monocyte tethering by P-selectin regulates monocyte chemotactic protein- 1 and tumor necrosis factor-alpha secretion: Signal integration and NF-kappa B translocation
28. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis
29. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation
30. Acetyl glyceryl ether phosphorylcholine: Intravascular alterations following intravenous infusion into the baboon
31. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation
32. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine
33. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin
34. Production of platelet-activating factor by human vascular endothelial cells: Evidence for a requirement for specific agonists and modulation by prostacyclin
35. Integrin signaling: The platelet paradigm
36. Signal-dependent translation of a regulatory protein, Bc1-3, in activated human platelets
37. Integrin-dependent control of translation: Engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets
38. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets. A checkpoint for translational control
39. Endothelial cell interactions with granulocytes: Tethering and signaling molecules
40. Leukocyte-endothelial adhesion molecules
41. Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion
42. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
43. IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1 alpha, RANTES, and PAF but inhibits migration to MCP-1: A regulatory role for endothelium-derived MCP-1
44. Cytokine regulation of endothelial cell function: From molecular level to the bedside
45. Platelet-activating factor: A signaling molecule for leukocyte adhesion
46. Oxygen metabolites and vascular damage
47. Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils
48. mTOR dependent translation of interleukin-6 receptor-a mRNA in human polymorphonuclear leukocytes
49. Atherosderosis - An inflammatory disease
50. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes
51. Activated platelets signal chemokine synthesis by human monocytes
52. Molecular mechanisms of juxtacrine cell signaling in microvascular responses and inflammation
53. The release of platelet-activating factor from human endothelial cells in culture
54. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIb-beta3 and stimulated by platelet-activating factor
55. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process
56. Platelet-activating factor: A mediator for clinicians
57. Effect of WEB 2086 on leukocyte adherence in response to hemorrhagic shock in rats
58. Platelet-activating factor (PAF) in experimental and clinical sepsis
59. P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia
60. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide
61. Intravascular release of platelet activating factor in children with sepsis
62. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia
63. Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists
64. Platelet-activating factor and phospholipase A2, in patients with septic shock and trauma
65. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis
66. Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome
67. Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure
68. Functional alpha4-integrin: A newly identified pathway of neutrophil recruitment in critically ill septic patients
69. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group
70. Effects of the PAF antagonists, ginkgolides (BN 52063, BN 52021), in various clinical interactions
71. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
72. Oxidized LDL contains inflammatory PAF-like phospholipids
73. Novel leukocyte agonists are released by endothelial cells exposed to peroxide
74. Platelet-activating factor acetylhydrolases
75. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase
76. Inflammation: A signal terminator
77. Human plasma platelet-activating factor acetylhydrolase: Purification and properties
78. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma
79. Mammalian platelet-activating factor acetylhydrolases
80. Platelet-activating factor acetylhydrolase increases during macrophage differentiation: A novel mechanism that regulates accumulation of platelet-activating factor
81. Human macrophages secret platelet-activating factor acetylhydrolase
82. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation
83. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma
84. PAF acetylhydrolase gene polymorphisms and asthma severity
85. The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: Anti-inflammatory effects of human PAF-acetylhydrolase
86. Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase
87. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281->Arg mutation
88. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor
89. Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages
90. The Phase II Pafase ARDS Prevention Study Group: Recombinant platelet activating factor acetylhydrolase (PAFASE) decreases the incidence of acute respiratory distress syndrome (ARDS) and 28-day all causes mortality